Citation Impact
Citing Papers
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
2002
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
2004
Adding pharmacogenomics to the development of new marine-derived anticancer agents
2006
Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
2010
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Pharmacology of LY315920/S-5920, [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1 H-indol-4-yl]oxy]acetate, a Potent and Selective Secretory Phospholipase A2Inhibitor: A New Class of Anti-Inflammatory Drugs, SPI
1999
Thiazolidinediones
2004 Standout
S-1 in the treatment of pancreatic cancer
2014
Cardiotoxic effects of anthracycline–taxane combinations
2003
Pancreatic cancer
2004 Standout
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
2010
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters
2005
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
2006
Biaryl diacid inhibitors of human s-PLA2 with anti-inflammatory activity
2000
Pancreatic cancer
2020 Standout
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
2006
In vivo MRI of cancer cell fate at the single‐cell level in a mouse model of breast cancer metastasis to the brain
2006
Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy
2012
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Drug development from marine natural products
2008 Standout
Flavonoids as Phospholipase A2 Inhibitors: Importance of Their Structure for Selective Inhibition of Group II Phospholipase A2
1997
Trabectedin
2007
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma
2004
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Pancreatic cancer
2016 Standout
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
2008
Ternary Dinuclear Copper(II) Complexes of a Hydroxybenzamide Ligand with Diimine Coligands: the 5,6-dmp Ligand Enhances DNA Binding and Cleavage and Induces Apoptosis
2011
Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer
2007
Selective inhibition of group II phospholipase A2 by quercetin
1993
Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy
2013
DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464
2002
Scalaradial, a Dialdehyde‐Containing Marine Metabolite That Causes an Unexpected Noncovalent PLA2 Inactivation
2007
Pancreatic Adenocarcinoma
2014 Standout
Risk factors for brain relapse in patients with metastatic breast cancer
2004
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Marine pharmacology in 2001–2: antitumour and cytotoxic compounds
2004
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
1994 StandoutNature
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Structure-antioxidant activity relationships of flavonoids and phenolic acids
1996 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
2010
The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033
2002
Capecitabine: A review
2005
JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin
2002
The Benefits of Frequent Positive Affect: Does Happiness Lead to Success?
2005 Standout
Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2
1997
Recent developments in the field of antitumour anthracyclines
2001
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
2008
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma1
2006
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
1995 StandoutNobel
Pancreatic Cancer
2010 Standout
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Current strategies in the management of hormone refractory prostate cancer
2003
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Natural products to drugs: natural product derived compounds in clinical trials
2005
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Suppression of inflammatory responses to 12‐O‐tetradecanoylphorbol‐13‐acetate and carrageenin by YM‐26734, a selective inhibitor of extracellular group II phospholipase A2
1993
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
2001
Metastatic colonization by circulating tumour cells
2016 StandoutNature
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
2003
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
2007
Preservation of Fertility in Patients with Cancer
2009 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Cancer related inflammation: The macrophage connection
2008
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
2002
Update on tubulin-binding agents
2005
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer
2008
Pancreatic cancer
2011 Standout
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
Endothelin stimulates prostaglandin endoperoxide synthase-2 mRNA expression and protein synthesis through a tyrosine kinase-signaling pathway in rat mesangial cells.
1994
Fluorine in medicinal chemistry
2007 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Prevention of Lipopolysaccharide-Induced Lethal Toxicity by Tyrosine Kinase Inhibitors
1994 Science
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Impaired TGF-β Responses in Peripheral T Cells of Gαi2−/− Mice
2005 StandoutNobel
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
2005
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
2008
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
2007
Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent.
2000
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
2005
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Formation and Antitumor Activity of PNU-159682, A Major Metabolite of Nemorubicin in Human Liver Microsomes
2005
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Agonist-specific alterations in receptor–phospholipase coupling following inactivation of Gi2α gene
1998
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
2007
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
1999
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
2009
CNS Metastases in Breast Cancer
2004
Works of Jean Bauer being referenced
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
2001
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
1998
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex
2000
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study
1997
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)
1999
Pharmacological characterization of WAY-121,520: A potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2)
1993
Cellular and Topical in vivo Inflammatory Murine Models in the Evaluation of Inhibitors of Phospholipase A<sub>2</sub>
1995
Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer
1994
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration
1998
Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial
2004
Structure-activity relationships leading to WAY-121,520, a tris aryl-type, indomethacin-based, phospholipase A2 (PLA2)/leukotriene biosynthesis inhibitor
1993
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study
1993
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study
2000
Regulation of eicosanoid biosynthesis in the macrophage
1993
Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapy
2005
Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors
2002
Analogs of the marine natural product scalaradial lacking the α,β-unsaturated aldehyde: effects on human synovial fluid phospholipase A2 and macrophage lipid mediator production
1994
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
2007
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
2005
Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer
1999
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
2000
Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer
2004
Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer
2004
Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.
1991
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
2003
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008